Adveq
Adveq, founded in 1997, is a prominent asset manager specializing in investments in private equity and real asset funds on a global scale. The firm offers tailored investment solutions that enable clients to access specific private market segments worldwide. With a strong track record, Adveq has invested in over 400 funds, consistently delivering returns across various economic conditions. Its clientele consists primarily of institutional investors, including pension funds, insurance companies, family offices, and other financial institutions from Europe, North America, and the Asia-Pacific region. Adveq has cultivated long-lasting relationships with many of its investors, establishing itself as a trusted partner in private market investing. The company operates offices in Zurich, Frankfurt, London, New York, Beijing, Shanghai, and Hong Kong, alongside an agent relationship in Sydney.
Araris Biotech
Seed Round in 2020
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
Araris Biotech
Seed Round in 2019
Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering drugs directly to targeted antibodies. This innovative approach allows for the creation of next-generation ADCs that are both safe and effective for treating various diseases, including cancer. Araris' platform enables the production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, allowing for rapid development and manufacturing processes. The technology is supported by two patents and focuses on site-specific conjugation, enabling the use of readily available antibodies. This streamlined production method facilitates quick quality control and analysis, enhancing the overall efficiency and reliability of ADC development.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.